Tyrosine kinase inhibitor (TKI), a lung cancer therapeutic drug that is researched and applied in the clinic in recent years to target the blood vessels of tumors, is a kind of targeted therapeutic drug. The so-called targeted therapy refers to the fact that antitumor drugs kill tumor cells by targeting the specific sites of tumors and having targeted effects on them. As a result, all therapeutic methods aimed at the tumor area can be called regionally targeted therapy, including three-dimensional stereotactic radiotherapy, argon helium knife therapy, interventional chemotherapy, radiofrequency therapy and so on [1-2]. The clinical application of these methods has benefited from the development of medical equipment and technology to achieve the purpose of "precision strike" on the tumor. For patients with stage IIIb and IV lung cancer confined to the thoracic cavity who have lost the opportunity for surgical treatment, it is difficult to achieve complete or partial remission of the tumor through systemic chemotherapy. Regional targeting is actually a "precise strike" against the tumor area, which has the advantages of fast effect, mild systemic toxicity and easy to be tolerated by patients. CTT can significantly enhance the local therapeutic effect, improve the quality of life and the degree of tolerance to chemotherapy, without the prolongation of disease progression.